Abstract Human epididymis protein 4 (HE4) is a novel tumour marker in epithelial ovarian
cancer (EOC). Data on its profile and predictive potential for subsequent outcome after …

Primary chemotherapy treatment response monitoring in advanced epithelial ovarian cancer
(EOC) is currently based on CT-imaging and serum CA125 values. Serum HE4 profile …

Objectives This study aimed to evaluate serum human epididymis protein 4 (HE4) changes
during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff …

Epithelial ovarian cancer (EOC) remains the deadliest form of gynecological cancers.
Optimal tumor debulking, no matter the primary or the interval, is the most important …

Background Ovarian cancer (OC) is considered the most lethal gynecological cancer, of
which more than 65% cases are diagnosed in advanced stages, requiring platinum-based …

Objective Human epididymis protein 4 (HE4) is a validated, complementary biomarker to
cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently …

Background The aim of this study is to evaluate a new tumour marker, HE4, and to compare
it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty …

OBJECTIVES: Epithelial ovarian cancer (EOC) is the major cause of death due to
gynecological malignancies. The most important prognostic factors are residual tumor mass …

Objective Human epididymis protein 4 (HE4) is a promising novel serum biomarker for the
detection of early-stage epithelial ovarian cancer (EOC) and for the differential diagnosis …

Clinical utility of new biomarkers often requires the identification of their optimal threshold.
This external validation study was conducted to assess the performance of the preoperative …